Actively Recruiting
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-10-15
2070
Participants Needed
1
Research Sites
1353 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
S
Southern Illinois University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
CONDITIONS
Official Title
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Neuroblastic tumors diagnosed according to the International Neuroblastoma Staging System
- Clinically suspected neuroblastic tumors
- Patients receiving naxitamab as part of their standard care (for PK draws only)
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
N
Nai-Kong Cheung, M.D., Ph.D.
CONTACT
S
Shakeel Modak, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here